Press Releases

27.02.2017

The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today first combination data of its TLR9 agonists EnanDIM® with a checkpoint inhibitor.

17.02.2017

The biotechnology company MOLOGEN (ISIN DE0006637200; Frankfurter Stock Exchange Prime Standard: MGN) will present a poster with the title “Combination of TLR9 agonists EnanDIM with checkpoint inhibitors for cancer immunotherapy" at the 2017...

16.02.2017

The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today that its partner, the Danish Aarhus University Hospital, presented new data on the TEACH study at the annual Conference on Retroviruses...

13.02.2017

Dr Matthias Baumann MD will join the Executive Board of biotechnology Company MOLOGEN AG (ISIN DE0006637200, Frankfurt Stock Exchange Prime Standard: MGN) as Chief Medical Officer (CMO) on 1 May 2017. Dr Baumann’s areas of responsibility within the...

23.01.2017

The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today first combination data of its TLR9 agonist lefitolimod with checkpoint inhibitors.

10.01.2017

• Gilead Sciences, Inc. grant for Aarhus University Hospital • Funding for a novel “kick-and-kill“ concept of HIV eradication • Lefitolimod to be combined with new virus-neutralizing antibodies

   

Displaying results 15 bis 20 von 20

previous

Page 1

Page 2

Page 3

   

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.